In summary, this is the first report demonstrating the reproducibility and feasibility of using autologous NKAE cells bearing NKG2D-CAR to treat MM and showing that CAR-NKAE cells are a better strategy against MM than memory CAR-T cells. This evidence concerns the gene KLRK1 and Miyoshi myopathy.